Clinical Trial: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN): a Retrospective Study of Patients Diagnosed in France From 2000 to 2013

Brief Summary:

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare disease characterized by an aggressive clinical behavior and a poor prognosis. It predominantly affects elderly males with an average age of 67 years at diagnosis and the affected organs are usually the skin, bone marrow, lymph nodes and the central nervous system. Patients with BPDCN have poor outcomes with median overall survival (OS) ranging in the largest series of patients from 8 to 12 months.

Patient care must be defined in this pathology. Despite 40%-90% complete remission (CR) rates after initial chemotherapy, relapses are almost inevitable.

The investigators have developed a national network to collect clinical and biological data of French patients diagnosed with BPDCN.


Detailed Summary:
Sponsor: Centre Hospitalier Universitaire de Besancon

Current Primary Outcome: description of the efficacy of treatments for BPDCN [ Time Frame: from the diagnosis to death or until June 2013, date of end of data collection ]

Measurement of the overall survival for all patients from the date of diagnostic until death or end of data collection


Original Primary Outcome: Same as current

Current Secondary Outcome:

  • description of clinical profiles of patients [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
    presence of cutaneous lesions
  • description of biological profiles of patients [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
    immunophenotyping profile
  • complete remission rate [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
  • mean duration of the first remission [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
  • survival without events [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
  • non-responders rate [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
  • time interval between two treatments [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]
  • mortality without relapse [ Time Frame: from the diagnosis to death or until June 2013, end of data collection ]


Original Secondary Outcome: Same as current

Information By: Centre Hospitalier Universitaire de Besancon

Dates:
Date Received: July 21, 2016
Date Started: January 2014
Date Completion:
Last Updated: August 4, 2016
Last Verified: July 2016